The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
DUBLIN, Ireland, February 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the upcoming 11 th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 2.45 pm Eastern Time. The event will be held
DUBLIN, Ireland, March 11, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 8.00 am Eastern Time.
DUBLIN, Ireland, April 8, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for AMR101 (ultra-pure ethyl- EPA) in patients with Huntington’s disease.
Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial DUBLIN, Ireland, May 6, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment
Amarin Announces $2.6 Million Bridge Financing DUBLIN, Ireland, May 26, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has signed a term sheet for a private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $2.6 million with certain existing
Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million DUBLIN, Ireland, July 22, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has revised the terms of the previously announced non-binding term sheet relating to the private placement of
Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that on July 6, 2009, the Company received a written notification from the Nasdaq Stock Market stating that it is not